Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma
Carcinoma, Squamous Cell
Combined Modality Therapy
Head and Neck Neoplasms
Maximum Tolerated Dose
Docetaxel at a dose of 60 mg/m(2) and vinorelbine at a dose of 45 mg/m(2), both given every 2 weeks, can be combined safely to achieve Phase II dose intensity of both agents. An ongoing Phase II trial will define the activity of this treatment combination.